Key Points
- SVP Lynette Holzbaur purchased 26,448 shares of Organon on May 6 at an average price of $13.35 (≈$353,081), boosting her stake to 52,851 shares — a 100.17% increase — per an SEC filing.
- Organon missed Q1 estimates, reporting $0.71 EPS versus $0.83 expected and $1.46B revenue versus $1.49B, with revenue down 3.5% year-over-year.
- The company declared a $0.02 quarterly dividend (annualized $0.08, ~0.6% yield) and faces mixed analyst views — MarketBeat shows an average rating of "Reduce" with an average price target of $11.40, though some firms have raised targets to $14.00.
Organon & Co. (NYSE:OGN - Get Free Report) SVP Lynette Holzbaur bought 26,448 shares of Organon & Co. stock in a transaction dated Wednesday, May 6th. The stock was purchased at an average price of $13.35 per share, with a total value of $353,080.80. Following the purchase, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Organon & Co. Stock Performance
NYSE OGN opened at $13.35 on Friday. Organon & Co. has a 1 year low of $5.69 and a 1 year high of $13.44. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.23. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of 14.35, a PEG ratio of 1.24 and a beta of 1.57. The company has a fifty day moving average price of $8.00 and a 200-day moving average price of $7.82.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business's revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.02 EPS. As a group, equities research analysts predict that Organon & Co. will post 3.23 EPS for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.'s dividend payout ratio is presently 8.60%.
Analyst Ratings Changes
Several equities analysts recently weighed in on OGN shares. Piper Sandler upgraded shares of Organon & Co. from an "underweight" rating to a "neutral" rating and increased their price target for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Barclays increased their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research report on Tuesday, February 24th. Wall Street Zen lowered shares of Organon & Co. from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. BNP Paribas Exane restated a "neutral" rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Finally, Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Four analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $11.40.
View Our Latest Stock Report on Organon & Co.
Institutional Investors Weigh In On Organon & Co.
Institutional investors have recently added to or reduced their stakes in the business. Sector Gamma AS purchased a new stake in Organon & Co. during the third quarter valued at about $5,807,000. Gotham Asset Management LLC lifted its holdings in Organon & Co. by 37.2% during the third quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company's stock valued at $39,657,000 after purchasing an additional 1,007,691 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company's stock valued at $383,715,000 after purchasing an additional 3,650,860 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Organon & Co. during the third quarter valued at about $2,000,000. Finally, Poehling Capital Management INC. lifted its holdings in Organon & Co. by 57.7% during the third quarter. Poehling Capital Management INC. now owns 317,748 shares of the company's stock valued at $3,394,000 after purchasing an additional 116,289 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.
About Organon & Co.
(
Get Free Report)
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
